Edmond de Rothschild Investment Partners
EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN GLYCOVAXYN TO GSK
Edmond de Rothschild Investment Partners / Key word(s): Mergers & Acquisitions
PRESS RELEASE
February 11th, 2015 EDMOND DE ROTHSCHILD INVESTMENT PARTNERS SELLS ITS PARTICIPATION IN GLYCOVAXYN, TO GSK. This operation is the seventh trade sale of BioDiscovery 3, the fifteenth from the BioDiscovery funds Edmond de Rothschild Investment Partners announced today that its BioDiscovery 3 portfolio company, GlycoVaxyn AG, a privately held specialist vaccine biopharmaceutical company, has been acquired by GlaxoSmithKline (GSK) in an all-cash transaction valuing the company at approximately $212 million. GlycoVaxyn, founded in 2004, is a spin out of the Swiss Polytechnic Institute of Zürich. It has developed a biological conjugation platform which enables the development of a new generation of conjugate vaccines against major bacterial infections. Vaccines this type are protecting children and adults against several infections among others pneumonia, meningitides, and the role of vaccination to prevent bacterial infections is becoming increasingly important with the development of resistance to antibiotic treatments. The company which signed a major collaboration with GSK in 2012, is in Phase I with a vaccine candidate against E. coli infections and is expected to initiate a Phase I for a vaccine against Shigellosis (severe diarrhea) in the US soon. Edmond de Rothschild Investment Partners led the series B round of Glycovaxyn in 2009. Glycovaxyn was the second investment of BioDiscovery 3, a specialized life science investment fund managed by Edmond de Rothschild Investment Partners. Raised in 2008, the Fund has invested from 2008 to 2012 in a portfolio of 14 companies. So far seven of these companies have been sold through private transactions, four have been listed on public financial markets, and the remaining three are still privately held active companies. Edmond de Rothschild Investment Partners is the private equity affiliate of the Edmond de Rothschild Group, which is specialized in asset management and private banking (EUR 133.6bn under management, nearly 2,800 employees spread across 31 offices, branches and subsidiaries throughout the world). Founded in 1953, the Group has been chaired since 1997 by Baron Benjamin de Rothschild. Paris-based Edmond de Rothschild Investment Partners is dedicated to minority investments into privately-owned companies. It currently has more than EUR1.3 billion under management which is being invested primarily as life sciences venture capital and growth capital. Within Edmond de Rothschild Investment Partners, its Life Sciences Team of eight professionals brings together over 60 years of experience in the Life Science industry and more than 100 years of private equity and venture capital experience. The Team has raised EUR450 million through its Biodiscovery franchise and is currently investing BioDiscovery 4. Since inception in 2001, BioDiscovery Funds have invested in 49 companies, of which 15 have been sold and 14 listed on public financial markets. 17 are still active in the portfolios. BioDiscovery Funds, including BioDiscovery 4, are venture capital funds dedicated to professional investors. These funds are not authorized by the Autorité des Marchés Financiers and may adopt special investment rules. For more information: www.edrip.fr Edmond de Rothschild Investment Partners 2015-02-11 Dissemination of a Corporate News, transmitted by DGAP – a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Media archive at www.dgap-medientreff.de and www.dgap.de |
321793 2015-02-11 |